I'd rather explain it without talking about obstacles.
Earlier, there was a brief discussion of the Quebec Court of Appeal's decision, which was very clear about the importance of observing areas of jurisdiction.
We even received, during the various consultation periods preceding the final one, a significant number of submissions from groups of patients who were very concerned about access to medicines. It therefore struck me as important to take the time to meet our legal obligations pursuant to subsection 96(5) and to conduct a significant consultation process.
Not only must we meet with and listen to the stakeholders, but also make sure that the guidelines we are going to introduce will survive any court proceeding that might subsequently be initiated.